Biological screening in the U.S. Army antimalarial drug development program.
The methods of testing drugs in the United States Army Antimalarial Drug Development Program are described. To date over two hundred thousand compounds have been screened. For each 3,000 compounds evaluated in the primary screen, only 1 is assessed for efficacy in the final test system. Of those potential antimalarials assessed in this last system, only about half are deemed worthy of preclinical toxicological evaluation.
D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001681:Biological Assay; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D005493:Folic Acid Antagonists / Q000032:analysis; D000882:Haplorhini; D008288:Malaria / Q000188:drug therapy / Q000469:parasitology; D051379:Mice; D008813:Mice, Inbred ICR; D008887:Military Medicine; D010962:Plasmodium berghei; D010963:Plasmodium falciparum / Q000187:drug effects; D010966:Plasmodium vivax; D014481:United States
D000962:Antimalarials; D005493:Folic Acid Antagonists